Effect of deferiprone on urinary zinc excretion in multiply transfused children with thalassemia major.
A prospective multi-centric study was conducted to determine if iron-chelating agent deferiprone also chelates zinc. Twenty four-hour urinary zinc levels were compared in multiply transfused children with thalassemia major not receiving any chelation therapy (Group A, n = 28), those receiving deferiprone (Group B, n = 30) and age and sex-matched controls of subjects in Group B (Group C, n = 29) by a colorimetric method. The 24-hour mean urinary excretion of zinc was significantly higher in Group B than in the other two groups indicating that deferiprone chelates zinc.
Bartakke
Sandip
S
Department of Pediatrics, Seth G.S. Medical College and KEM Hospital, Mumbai, India.
Bavdekar
S B
SB
Kondurkar
Pratima
P
Muranjan
Mamta N
MN
Manglani
Mamata V
MV
Sharma
Ratna
R
D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D000077543:Deferiprone; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D011728:Pyridones / Q000627:therapeutic use*; D019233:Retreatment; D013997:Time Factors; D015032:Zinc / Q000652:urine*; D017086:beta-Thalassemia / Q000628:therapy / Q000652:urine*
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D015032:Zinc